Upregulation of Phosphodiesterase 2A Augments T Cell Activation by Changing cGMP/cAMP Cross-Talk
Open Access
- 5 October 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Abstract
3′,5′-cyclic adenosine monophosphate (cAMP) is well-known for its diverse immunomodulatory properties, primarily inhibitory effects during T cell activation, proliferation, and production of pro-inflammatory cytokines. A decrease in cAMP levels, due to the hydrolyzing activity of phosphodiesterases (PDE), is favoring inflammatory responses. This can be prevented by selective PDE inhibitors, which makes PDEs important therapeutic targets for autoimmune disorders. In this study, we investigated the specific roles of PDE2A and PDE3B in the regulation of intracellular cAMP levels in different mouse T cell subsets. Unexpectedly, T cell receptor (TCR) activation led to a selective upregulation of PDE2A at the protein level in conventional T cells (Tcon), whereas no changes were detected in regulatory T cells (Treg). In contrast, protein expression of PDE3B was significantly higher in both non-activated and activated Tcon subsets as compared to Treg, with no changes upon TCR engagement. Live-cell imaging of T cells expressing a highly sensitive Förster resonance energy transfer (FRET)-based biosensor, Epac1-camps, has enabled cAMP measurements in real time and revealed stronger responses to the PDE2A inhibitors in activated vs non-activated Tcon. Importantly, stimulation of intracellular cGMP levels with natriuretic peptides led to an increase of cAMP in non-activated and a decrease of cAMP in activated Tcon, suggesting that TCR activation changes the PDE3B-dependent positive to PDE2A-dependent negative cGMP/cAMP cross-talk. Functionally, this switch induced higher expression of early activation markers CD25 and CD69. This constitutes a potentially interesting feed-forward mechanism during autoimmune and inflammatory responses that may be exploited therapeutically.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (SFB1328)
This publication has 49 references indexed in Scilit:
- Modulation of T cell immune functions by the prostaglandin E2 – cAMP pathway in chronic inflammatory statesBritish Journal of Pharmacology, 2012
- Cyclic AMP-mediated immune regulation — Overview of mechanisms of action in T cellsCellular Signalling, 2011
- Functional Regulatory T Cells Produced by Inhibiting Cyclic Nucleotide Phosphodiesterase Type 3 Prevent Allograft RejectionScience Translational Medicine, 2011
- FRET measurements of intracellular cAMP concentrations and cAMP analog permeability in intact cellsNature Protocols, 2011
- Anxiolytic Effects of Phosphodiesterase-2 Inhibitors Associated with Increased cGMP SignalingThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Persistent cAMP-Signals Triggered by Internalized G-Protein–Coupled ReceptorsPLOS Biology, 2009
- miR‐142‐3p restricts cAMP production in CD4+CD25− T cells and CD4+CD25+ TREG cells by targeting AC9 mRNAEMBO Reports, 2008
- Cyclic adenosine monophosphate is a key component of regulatory T cell–mediated suppressionJournal of Experimental Medicine, 2007
- Foxp3-dependent programme of regulatory T-cell differentiationNature, 2007
- Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: Analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipramCellular Signalling, 1996